EUVIMEDSkopri EUVIMED
Open access · CC BY-NC-ND 4.0

Virtual Screening and Zebrafish Phenotype‐Based Evaluation Argues Against Repurposing 4‐Phenylbutyrate for STXBP1 ‐Related Disorders

Aline Frick, Paige Whyte-Fagundes, Scott C Baraban iD

Pharmacology Research & Perspectives · 2026-06 · 14 (3)

DOI: 10.1002/prp2.70285 ↗

At a glance

Journal article in Pharmacology Research & Perspectives, published online on 2026-06-10. Written by Aline Frick and 2 co-authors. Institution: Department of Neurological Surgery & Weill Institute for Neuroscience, University of California, San Francisco, San Francisco, California, USA. Major MEDLINE topics: Phenylbutyrates, Munc18 Proteins. 46 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: NIH HHS, Savoy Foundation, STXBP1 Foundation.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Syntaxin‐binding protein 1 ( STXBP1 ) mutations lead to severe epilepsy, intellectual disability, developmental delay, and movement disorder. Effective treatments for these conditions do not exist. Recent studies in Munc18‐1 ( STXBP1 ) C. elegans models demonstrate that 4‐phenylbutyrate (4‐PBA) or related pharmacological chaperones stabilize Munc18‐1 protein levels and rescue locomotion deficits. These studies suggest a novel treatment strategy for these patients. Here, we used a stxbp1a zebrafish model with a profound movement disorder to screen 4‐PBA and alternative structural analogs identified using artificial intelligence (AI)‐based screening. Automated locomotion assays conducted on larval stxbp1a mutant zebrafish at 5 days post‐fertilization (dpf) confirm and extend the movement disorder endophenotype. Drug treatment (4‐PBA or 16 identified candidates) failed to rescue the stxbp1a mutant zebrafish locomotion deficit. Electrophysiology studies in a stxbp1b zebrafish model characterized by spontaneous seizure activity (i.e., epilepsy) failed to detect a reduction in ictal‐like events with 4‐PBA treatment. Taken together, our results suggest caution in repurposing 4‐PBA or related compounds for the treatment of STXBP1 disorders.

Subjects

MeSH terms (MEDLINE)

PhenylbutyratesMunc18 ProteinsAnimalsZebrafishLocomotionPhenotypeDisease Models, AnimalDrug RepositioningMutationHumansEpilepsy

Author keywords

behaviorpharmacologyseizurezebrafish

Substances

PhenylbutyratesMunc18 Proteins4-phenylbutyric acidSTXBP1 protein, human

Authors and institutions

  • Department of Neurological Surgery & Weill Institute for Neuroscience, University of California, San Francisco, San Francisco, California, USA.
  • Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, the Netherlands.
  • Helen Wills Institute of Neuroscience, University of California, Berkeley, San Francisco, California, USA.

ORCID profiles: Scott C Baraban

Funding

  • NIH HHS
  • Savoy Foundation
  • STXBP1 Foundation
  • National Institutes of Health

Cite

APA

Frick, A., Whyte-Fagundes, P., & Baraban, S. C. (2026). Virtual Screening and Zebrafish Phenotype‐Based Evaluation Argues Against Repurposing 4‐Phenylbutyrate for STXBP1 ‐Related Disorders. Pharmacology Research & Perspectives, 14(3). https://doi.org/10.1002/prp2.70285

Vancouver

Frick A, Whyte-Fagundes P, Baraban SC. Virtual Screening and Zebrafish Phenotype‐Based Evaluation Argues Against Repurposing 4‐Phenylbutyrate for STXBP1 ‐Related Disorders. Pharmacology Research & Perspectives. 2026;14(3). doi:10.1002/prp2.70285

BibTeX
@article{Frick2026,
  author = {Frick, Aline and Whyte-Fagundes, Paige and Baraban, Scott C},
  title = {Virtual Screening and Zebrafish Phenotype‐Based Evaluation Argues Against Repurposing 4‐Phenylbutyrate for STXBP1 ‐Related Disorders},
  journal = {Pharmacology Research & Perspectives},
  year = {2026},
  volume = {14},
  number = {3},
  doi = {10.1002/prp2.70285}
}
Start for free →